In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janelle Hart

Managing Editor, Custom Content

Boston, MA

Janelle is Managing Editor of Custom Content. She previously worked in both publications and marketing/advertising in the medical communications field, with a focus on pharmaceuticals. Originally from New Jersey, Janelle attended Miami University for undergrad and is now pursuing a Masters in Publishing and Writing at Emerson College in Boston, Massachusetts, where she currently resides. In her spare time, Janelle enjoys watching films and cooking.

Latest From Janelle Hart

Next-Gen ADCs: Araris CEO Highlights Potential In Linker Technology

In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.

Rising Leaders Innovation

Exploring Alltrna’s Rare Disease Platform

Michelle Werner, CEO of Alltrna, sat down with In Vivo to discuss rare disease as an increasingly important area of study, innovation in the space and how the emerging biotech hopes to impact the treatment landscape.

Rare Diseases Rising Leaders
See All